HK1186412A1 - 鎳紋蛋白用於治療異常性疼痛、痛覺過敏、自發性疼痛和幻痛的用途 - Google Patents

鎳紋蛋白用於治療異常性疼痛、痛覺過敏、自發性疼痛和幻痛的用途

Info

Publication number
HK1186412A1
HK1186412A1 HK13114017.5A HK13114017A HK1186412A1 HK 1186412 A1 HK1186412 A1 HK 1186412A1 HK 13114017 A HK13114017 A HK 13114017A HK 1186412 A1 HK1186412 A1 HK 1186412A1
Authority
HK
Hong Kong
Prior art keywords
pain
meteorin
allodynia
hyperalgesia
treatment
Prior art date
Application number
HK13114017.5A
Other languages
English (en)
Inventor
Teit E Johansen
Lars Ulrik Wahlberg
Jesper Roland Jrgensen
Original Assignee
Hoba Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoba Therapeutics Aps filed Critical Hoba Therapeutics Aps
Publication of HK1186412A1 publication Critical patent/HK1186412A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK13114017.5A 2010-10-01 2013-12-18 鎳紋蛋白用於治療異常性疼痛、痛覺過敏、自發性疼痛和幻痛的用途 HK1186412A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070423 2010-10-01
US39079110P 2010-10-07 2010-10-07
PCT/DK2011/050369 WO2012041328A1 (en) 2010-10-01 2011-09-30 Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Publications (1)

Publication Number Publication Date
HK1186412A1 true HK1186412A1 (zh) 2014-03-14

Family

ID=59278857

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13114017.5A HK1186412A1 (zh) 2010-10-01 2013-12-18 鎳紋蛋白用於治療異常性疼痛、痛覺過敏、自發性疼痛和幻痛的用途

Country Status (10)

Country Link
US (3) US8404642B2 (zh)
EP (1) EP2621512B1 (zh)
JP (2) JP6149226B2 (zh)
KR (1) KR101886029B1 (zh)
CN (2) CN108079279B (zh)
AU (1) AU2011307488B2 (zh)
CA (1) CA2813013C (zh)
ES (1) ES2584068T3 (zh)
HK (1) HK1186412A1 (zh)
WO (1) WO2012041328A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2195013T3 (da) 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
KR102075881B1 (ko) 2011-09-05 2020-02-11 호바 세라퓨틱스 에이피에스 이질통, 통각과민증, 자발통 및 환상통의 치료
CN103685771A (zh) * 2013-12-13 2014-03-26 苏州士丹尼信息技术有限公司 一种集成的信息交流系统
CN107184956B (zh) * 2016-03-14 2020-09-08 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在防治脓毒血症方面的应用
EP3921651A2 (en) * 2019-02-08 2021-12-15 Biolegend, Inc. Methods for detecting meteorin-beta activity
JP2024518433A (ja) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス 化学療法誘発性神経障害性疼痛の予防及び治療
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
DE69221484T2 (de) 1991-04-25 1998-02-19 Univ Brown Res Found Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
WO1993022437A1 (en) 1992-04-30 1993-11-11 N.V. Innogenetics S.A. New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
JP2002516295A (ja) 1998-05-27 2002-06-04 アビジェン， インコーポレイテッド Ａａｖベクターの対流増加送達
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
EP1225224A4 (en) 1999-10-01 2004-03-24 Kyowa Hakko Kogyo Kk DNA THE SHEAR RESPONSE
EP1233779A2 (en) 1999-11-30 2002-08-28 Innogenetics N.V. New uses of suppressive macrophage activation factors
WO2001055440A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2392757A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2403901A1 (en) 2000-05-02 2001-11-08 Human Genome Sciences, Inc. 29 human secreted proteins
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
EP1395279B1 (en) 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US20050208062A1 (en) 2001-12-21 2005-09-22 Yongming Sun Compositions and methods relating to hepatic specific genes and proteins
WO2004035732A2 (en) 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2006519620A (ja) 2003-03-04 2006-08-31 アークチュラス バイオサイエンス，インコーポレイティド 乳がんにおけるｅｒ状態の弁別特性
WO2005095460A2 (en) 2004-03-30 2005-10-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
PL1745069T3 (pl) 2004-03-30 2009-10-30 Nsgene As Zastosowanie terapeutyczne czynnika wzrostu NSG33
US20070161696A1 (en) * 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP1883446B8 (en) 2005-05-17 2017-11-15 Gloria Therapeutics Sarl An implantable therapy system for treating a living being with an active factor
JP2009513584A (ja) 2005-10-28 2009-04-02 エヌエスゲーネ・アクティーゼルスカブ Ｇｄｎｆの送達のための移植可能な生体適合性免疫隔離ビヒクル
JP2009527576A (ja) 2006-02-24 2009-07-30 ネオフアーム・インコーポレイテツド カルジオリピン調製の方法および工程
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
KR100823156B1 (ko) 2007-05-02 2008-04-22 재단법인서울대학교산학협력재단 메테오린을 유효성분으로 포함하는 혈관신생 억제제
WO2008136541A1 (en) * 2007-05-02 2008-11-13 Snu R&Db Foundation Angiogenesis inhibitor comprising meteorin as an active ingredient
WO2009069764A1 (ja) * 2007-11-30 2009-06-04 National University Corporation Chiba University オピオイド鎮痛剤
DK2195013T3 (da) * 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
EP2334315B1 (en) * 2008-09-03 2023-01-18 NoNO Inc. Agents and methods for treatment of pain
TW201031650A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma

Also Published As

Publication number Publication date
JP2013543378A (ja) 2013-12-05
JP2017052783A (ja) 2017-03-16
AU2011307488B2 (en) 2015-08-20
US8404642B2 (en) 2013-03-26
US9314502B2 (en) 2016-04-19
AU2011307488A1 (en) 2013-05-02
CN103269708A (zh) 2013-08-28
US20130303459A1 (en) 2013-11-14
US20120108518A1 (en) 2012-05-03
KR20130108380A (ko) 2013-10-02
CN108079279B (zh) 2022-04-12
EP2621512B1 (en) 2016-04-06
WO2012041328A1 (en) 2012-04-05
JP6149226B2 (ja) 2017-06-21
US8815810B2 (en) 2014-08-26
CA2813013A1 (en) 2012-04-05
ES2584068T3 (es) 2016-09-23
KR101886029B1 (ko) 2018-08-07
EP2621512A1 (en) 2013-08-07
JP6247734B2 (ja) 2017-12-13
CN108079279A (zh) 2018-05-29
CA2813013C (en) 2019-10-22
US20150202262A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
HK1186412A1 (zh) 鎳紋蛋白用於治療異常性疼痛、痛覺過敏、自發性疼痛和幻痛的用途
EP2425001A4 (en) ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
EP2629736A4 (en) FABRIC TREATMENT
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
ZA201208413B (en) Skin treatment composition
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
HK1215787A1 (zh) 用於治療疼痛的藥物組合
PL2407151T3 (pl) Kompozycja do leczenia zmian skórnych i/lub paznokci
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
EP2659879A4 (en) HAIR TREATMENT AGENT COMPOSITION
HK1199395A1 (zh) 異常性疼痛、痛覺過敏、自發性疼痛、和幻痛的治療
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
ZA201209298B (en) Hydroxyalkyl benzyl pyrazoles,and use thereof for the treatment of hyperproliferative and angiogenic diseases
EP3406242B8 (en) Tlr4 antagonist for use in the treatment of increased ammonia plasma levels
EP2560677A4 (en) COLD TREATMENT
ZA201208568B (en) Skin treatment composition
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
PL2599487T3 (pl) Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
LT2531124T (lt) Prietaisai odos pažeidimams gydyti
HK1214771A1 (zh) 用於治療皮膚病的製劑
HK1188565A1 (zh) 二芳基噠嗪酮衍生物、其製備方法及其用於人類治療的用途
PL2456445T3 (pl) Środek do leczenia chorób skóry
EP2544534A4 (en) COMPOSITIONS, METHODS AND DEVICES USED IN THE TREATMENT OF DYSMENORRHEA
GB201001376D0 (en) New compounds and medical uses